Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533210 | 1.00 | RAB9A (0.55) | RAB9AKDM4ENPC1SMN1; SMN2BCHE | |
| SCHEMBL5575172 | 0.85 | RAB9A (0.64) | RAB9AKDM4ENPC1SMN1; SMN2BCHE | |
| SCHEMBL3827791 | 0.80 | RAB9A (0.55) | RAB9AKDM4ENPC1SMN1; SMN2BCHE | |
| SCHEMBL11215851 | 0.78 | RAB9A (0.53) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL11215847 | 0.78 | RAB9A (0.53) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8947911 | 0.77 | RAB9A (0.33) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8947910 | 0.77 | RAB9A (0.33) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL18532429 | 0.77 | RAB9A (0.64) | RAB9AKDM4ENPC1SMN1; SMN2BCHE | |
| SCHEMBL8414209 | 0.76 | RAB9A (0.71) | RAB9AKDM4ENPC1SMN1; SMN2BCHE | |
| SCHEMBL15198025 | 0.76 | RAB9A (0.71) | RAB9AKDM4ENPC1SMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | claimed |
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | FINETECH LABORATORIES LTD | 2005-09-22 | — | — | US | claimed |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | FINETECH PHARMACEUTICAL LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-20090163596-A1 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | disclosed |
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | FINETECH LABORATORIES LTD | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | PTGIS, PTGES, PTGIR | RAB9A 3807/4885KDM4E 4475/4885NPC1 2047/4885 |
| US-20090163596-A1 | Bimatoprost crystalline form I | PTGER1, BBC3, CYP2A7 | RAB9A 4172/4885KDM4E 4792/4885NPC1 3989/4885 |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | PTGER1, BBC3, CYP2A7 | RAB9A 4172/4885KDM4E 4792/4885NPC1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.